ALS is a rare, progressing disease

Amyotrophic lateral sclerosis (ALS) is a rare, progressing disease in which motor neurons degenerate or die diminishing the signals that control muscle function.

Read more

New publication in the Journal of Cardiovascular Pharmacology: Working hypothesis for mechanisms of action of levosimendan in patients with ALS

A Review article summarizing the Potential of Levosimendan in the Management of ALS: Overview of a Working Hypothesis

Read more

LEVALS study results assessing the effects of oral levosimendan in patients with ALS published

The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.

Read more

Orion completes patient recruitment for the Phase III trial developing a drug for ALS

Patient trials under way on ALS treatment to support breathing capacity

The REFALS trial is studying the effects of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS).

Read more

Appetite for life

ALS study Webinar

Access Policy for ALS

Orion aims to build well-being in ALS by developing effective new treatments to help patients manage their illness and improve their quality of life.

Read more

ALS – symptoms and treatment

The beginning and progression of ALS symptoms vary between people. The treatment is planned by a multi-professional team in cooperation with the patient. The patients’ families need support as well.

Read more

Orion's R&D Pipeline
Orion R&D
Research for patient well-being
ALS
Drug development
Scientific publications
Clinical Research Privacy Statement
Orion Research Foundation